Search - tctmd.com

Displaying 61 - 80 of 682

Sort: Relevancy | Date

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

September 09, 2024

AI-Assisted Look at Coronary Inflammation on CT Refines CV Risk Assessment

News Daily News

AI-Assisted Look at Coronary Inflammation on CT Refines CV Risk Assessment

May 31, 2024

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

News Conference News ESOC 2024

TEMPO-2: Tenecteplase No Help in Mild Stroke With Proven Occlusion

May 23, 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

News Conference News ESOC 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

May 16, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

News Daily News

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

May 09, 2024

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

In Transporting Donor Hearts, SherpaPak Shows Promise Over Traditional Coolers

News Daily News

In Transporting Donor Hearts, SherpaPak Shows Promise Over Traditional Coolers

Yael L. Maxwell

April 18, 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

April 08, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

February 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

February 01, 2024

Across the Globe, Some Sex Gaps Still Seen in Congestive Heart Failure

News Daily News

Across the Globe, Some Sex Gaps Still Seen in Congestive Heart Failure

January 22, 2024

Top Coronary Artery Disease News of 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

December 2023 Dispatch for the CV Team

News Opinion CV Team Dispatch

December 2023 Dispatch for the CV Team

December 01, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial

Presentation TCT 2023

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial

Presenter: Giovanni De Maria

October 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.